159 related articles for article (PubMed ID: 16328513)
1. Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists.
Kontogeorgos G; Horvath E; Kovacs K; Coire C; Lloyd RV; Scheithauer BW; Smyth HS
Acta Neuropathol; 2006 Jan; 111(1):46-52. PubMed ID: 16328513
[TBL] [Abstract][Full Text] [Related]
2. Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.
Höfle G; Gasser R; Mohsenipour I; Finkenstedt G
Exp Clin Endocrinol Diabetes; 1998; 106(3):211-6. PubMed ID: 9710362
[TBL] [Abstract][Full Text] [Related]
3. Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists.
Hamester U; Saeger W; Lüdecke DK
Histol Histopathol; 1987 Apr; 2(2):135-42. PubMed ID: 2980713
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects.
Gruszka A; Pawlikowski M; Kunert-Radek J
Neuro Endocrinol Lett; 2001 Oct; 22(5):343-8. PubMed ID: 11600876
[TBL] [Abstract][Full Text] [Related]
7. Anejaculation as the presenting feature of pituitary microadenoma.
Nair S; Milsom S
Fertil Steril; 2008 Nov; 90(5):2012.e21-3. PubMed ID: 18394608
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic study of 123 cases of prolactin-secreting pituitary adenomas with special reference to multihormone production and clonality of the adenomas.
Ma W; Ikeda H; Yoshimoto T
Cancer; 2002 Jul; 95(2):258-66. PubMed ID: 12124824
[TBL] [Abstract][Full Text] [Related]
9. When to discontinue treatment of prolactinoma?
Wass JA
Nat Clin Pract Endocrinol Metab; 2006 Jun; 2(6):298-9. PubMed ID: 16932302
[No Abstract] [Full Text] [Related]
10. Aldosterone response to metoclopramide in patients with prolactinoma: effect of short-term bromocriptine treatment.
Zacharieva S; Stoeva I; Andreeva M; Kalinov K; Matrozov P; Andonova K
Methods Find Exp Clin Pharmacol; 1996 Nov; 18(9):593-7. PubMed ID: 9010834
[TBL] [Abstract][Full Text] [Related]
11. [Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics].
Fedorova NS; Abrosimov AY; Dzeranova LK; Pigarova EA; Dedov II
Arkh Patol; 2018; 80(3):34-39. PubMed ID: 29927438
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of prolactin-secreting macroadenomas with pergolide.
Freda PU; Andreadis CI; Khandji AG; Khoury M; Bruce JN; Jacobs TP; Wardlaw SL
J Clin Endocrinol Metab; 2000 Jan; 85(1):8-13. PubMed ID: 10634356
[No Abstract] [Full Text] [Related]
13. Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists.
Passos VQ; Fortes MA; Giannella-Neto D; Bronstein MD
Neuroendocrinology; 2009; 89(2):163-70. PubMed ID: 18791324
[TBL] [Abstract][Full Text] [Related]
14. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
[TBL] [Abstract][Full Text] [Related]
15. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
16. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
17. Dopamine agonists and valvular heart disease.
Cheung D; Heaney A
Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
[TBL] [Abstract][Full Text] [Related]
18. Pharmacologic resistance in prolactinoma patients.
Molitch ME
Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068
[TBL] [Abstract][Full Text] [Related]
19. Effect of dopamine agonist medication on prolactin producing pituitary adenomas. A morphological study including immunocytochemistry, electron microscopy and in situ hybridization.
Kovacs K; Stefaneanu L; Horvath E; Lloyd RV; Lancranjan I; Buchfelder M; Fahlbusch R
Virchows Arch A Pathol Anat Histopathol; 1991; 418(5):439-46. PubMed ID: 2035258
[TBL] [Abstract][Full Text] [Related]
20. Complete remission of macroprolactinoma after long-term medical therapy with dopamine agonists.
Iglesias P; Díez JJ
QJM; 2011 Aug; 104(8):721-2. PubMed ID: 20663808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
